The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | iFCG for first-line treatment of IGHV-mutated CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) in patients with previously untreated chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Dr Jain explains the key differences between the iFCG and the standard FCR regimens, and reveals a high rate of undetectable MRD with the iFCG regimen. This interview took place at the 18th International Workshop on CLL (iwCLL) Biennial Meeting, held in Edinburgh, UK.
